Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

SCOTUS Denies Amgen’s Bid to Revive Repatha Patents

  • Post author:PacConAdmin
  • Post published:May 18, 2023
  • Post category:Drug Industry Daily

The U.S. Supreme Court (SCOTUS) on Thursday struck down Amgen’s attempt to revive patents on its cholesterol medicine Repatha (evolocumab), effectively preventing the company from monopolizing an entire class of…

Continue ReadingSCOTUS Denies Amgen’s Bid to Revive Repatha Patents

FTC Deepens Probe of PBMs, House Advances Pricing Transparency Bill

  • Post author:PacConAdmin
  • Post published:May 18, 2023
  • Post category:Drug Industry Daily

The FTC and Congress were on the same drug pricing track this week as the trade commission extended an inquiry into pharmacy benefit managers’ (PBM) impact on the cost of…

Continue ReadingFTC Deepens Probe of PBMs, House Advances Pricing Transparency Bill

CDRH’s Shuren Aims to Put U.S. at Top of Novel Device Launches

  • Post author:PacConAdmin
  • Post published:May 18, 2023
  • Post category:Drug Industry Daily

CDRH Director Jeffrey Shuren aims to reverse a historical trend and make the U.S. the top destination for novel medical device launches, improving the center’s efficiency along the way. Source:…

Continue ReadingCDRH’s Shuren Aims to Put U.S. at Top of Novel Device Launches

EU GMP Report — May 2023

  • Post author:PacConAdmin
  • Post published:May 18, 2023
  • Post category:Drug Industry Daily

This monthly feature consists of excerpts from articles printed in GMP Newsletter LOGFILE, reprinted by permission of the publisher, GMP-Verlag Peither AG. Source: Drug Industry Daily

Continue ReadingEU GMP Report — May 2023

Warning Letter Cites Eye Drop Manufacturer for Lack of Sterile Environment

  • Post author:PacConAdmin
  • Post published:May 17, 2023
  • Post category:Drug Industry Daily

Pharmedica USA’s Phoenix, Ariz., drug manufacturing facility was cited by the FDA in a warning letter for lack of a sterile environment for producing its OTC eye drops and for…

Continue ReadingWarning Letter Cites Eye Drop Manufacturer for Lack of Sterile Environment

Califf: Diabetes, Weight Loss, Alzheimer’s Drugs Could Be “Major Game Changers”

  • Post author:PacConAdmin
  • Post published:May 17, 2023
  • Post category:Drug Industry Daily

FDA Commissioner Robert Califf said Alzheimer’s disease drugs and glucagon-like peptide-1 (GLP-1) agonists for diabetes and obesity could be “major game changers in the ongoing battle with chronic diseases that…

Continue ReadingCaliff: Diabetes, Weight Loss, Alzheimer’s Drugs Could Be “Major Game Changers”

Two New Draft Guidances Clarify Requirements for Pediatric Drug Development

  • Post author:PacConAdmin
  • Post published:May 17, 2023
  • Post category:Drug Industry Daily

Two draft guidances released by the FDA on Wednesday aim to reduce lag time between approval of a drug for adult use and its subsequent pediatric approval by clarifying requirements…

Continue ReadingTwo New Draft Guidances Clarify Requirements for Pediatric Drug Development

Digging Into Digital Therapeutics Trials: Advice for Sites and Sponsors

  • Post author:PacConAdmin
  • Post published:May 17, 2023
  • Post category:Drug Industry Daily

Clinical trial sites venturing into the growing field of digital therapeutics (DTx) need the appropriate infrastructure — as well as tech know-how and adaptability — while sponsors need to be…

Continue ReadingDigging Into Digital Therapeutics Trials: Advice for Sites and Sponsors

Meeting Planner — Week of May 15, 2023

  • Post author:PacConAdmin
  • Post published:May 17, 2023
  • Post category:Drug Industry Daily

Upcoming events in the coming weeks include six FDA advisory committee meetings as well as webinars and conferences on subjects ranging from IVDs and LDTs, developing SOPs and pharmaceutical quality…

Continue ReadingMeeting Planner — Week of May 15, 2023

Philips Concludes Recalled Sleep Therapy Devices Not Likely to Cause Harm

  • Post author:PacConAdmin
  • Post published:May 16, 2023
  • Post category:Drug Industry Daily

Philips Respironics reports risk assessments of its continuous positive airway pressure (CPAP) and bi-level positive airway pressure (BiPAP) sleep apnea therapy devices showed that degraded sound abatement foam on the…

Continue ReadingPhilips Concludes Recalled Sleep Therapy Devices Not Likely to Cause Harm
  • Go to the previous page
  • 1
  • …
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.